Endocrine Abstracts

Context: Cyproterone acetate (CPA) is an androgen receptor blocker often used for testosterone suppression as a part of gender-affirming hormonal treatment (GAHT) in transgender women. In recent years, more concerns have been raised towards an increased risk of meningioma development, linked to CPA use in higher doses (25 mg or more per day).Objectives: To determine if lower doses of CPA are equally effective in maintain...

Background: Since pelvic gender-affirming surgery (GAS) is no longer required for legal gender change, we expect a growing number of transgender men and gender nonbinary people who refrain from pelvic surgery. Little is known about the effects of long-term testosterone use on the reproductive organs. Polycystic ovaries and endometrial changes have been described in previous histology-based studies. Furthermore, cervical cancer screening (CCS) is still recommen...

Introduction: Transgender and gender diverse (TGD) people experience a gender identity which is different from the sex assigned at birth. Some transgender men (TM) can ask for testosterone to induce virilization and its effects on bone health are still to be fully elucidated. The aim of this systematic review and meta-analysis was to evaluate the changes on bone metabolism in a short-term period among TM starting testosterone. Methods: A systematic searc...